Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* primary renal transplant (not HLA identical)~* ages 18-60 years~Exclusion Criteria:~* recipient panel reactive antibody level \>10%~* recipient of a DCD kidney~* no prior organ transplant~* no multi-organ transplant recipient~* no subject who is currently receiving systemic corticosteroids~* no pregnant or lactating subjects~* no history of Hepatitis B, C or HIV positivity~* no recipient of a kidney with cold ischemia time \>36 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Campath 1H induction w/ Sirolimus immunosuppression (Type: EXPERIMENTAL): Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,

Based on this trial design, predict the completion outcome and termination type (if applicable).